Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

BARD1 Life Sciences lodges SPP and options prospectus (ASX:BD1)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that following the successful completion and issue of placement shares to sophisticated, institutional and profess...read more

TALi Digital - Company Update & Appendix 4C (ASX:TD1)

HIGHLIGHTS International growth strategy on-track with several strategic partnerships in key global markets currently in negotiations Early-stage product launch in India demonstrating strong c...read more

Immutep - Cleansing Notice (ASX:IMM)

This notice is given by Immutep Limited ACN 009 237 889 (Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). On 21 June 2021, the Company announced a non-unde...read more

Immutep - Completion of Placement - Tranche 2 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to announce it has completed the second tranche of its institutional placement (Placement), d...read more

BARD1 Life Sciences - Appendix 4C & Quarterly Activities Report (ASX:BD1)

Strong commercial progress: -- hTERT receipts of $184k for the period compared to previous quarter of $42k -- RUO1 EXO-NET® launched and exosome capture data presented at ISEV2021 in May 2021...read more

Immutep - Application for quotation of securities (ASX:IMM)

To view the application for quotation of securities, download the attached PDF.

BARD1 Life Sciences - Appendix 2A (ASX:BD1)

To view the Application for quotation of +securities, download the attached PDF.

BARD1 Life Sciences Collaborator Uni of QLD Announces Ovarian Cancer Data (ASX:BD1)

-- University of Queensland researchers have unveiled promising results for a potential exosome-based blood test for ovarian cancer -- BARD1’s RUO EXO-NET® product has been used by the re...read more

LBT Innovations - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:LBT)

Highlights for the Quarter Two APAS® Independence instruments sold in the UK to Health Services Laboratory US multi-laboratory purchasing opportunities - AdventHealth and Vizient EU Urin...read more

Chimeric Therapeutics licenses novel solid tumor CAR T therapy from Penn (ASX:CHM)

-- Chimeric has obtained the exclusive license to a novel CAR T for solid tumors from the University of Pennsylvania (Penn) -- The CDH17 CAR T has demonstrated the complete eradication of tumor cel...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics Limited (“the Company”) (ASX: CHM), a clinical stage cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 June 2021. ...read more

ImpediMed - Appendix 4C & Quarterly Activities Report (ASX:IPD)

To view the report, download the attached PDF.

Immutep - Change in substantial holding (ASX:IMM)

To view the Notice of change of interests of substantial holder, download the attached PDF.

Immutep - Proposed issue of securities (ASX:IMM)

To view the Proposed issue of securities, download the attached PDF.

Immutep - Results of EGM (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary in accordance wi...read more

Viewing: 1 - 15 of 200 Previous | Next